Pregabalin Capsule 75 mg
Pregabalin 75mg
Hard capsule · Prescription medication
Ahn-Gook New Pharm Co., Ltd.
MFDS item code 201906645 · Approved 2019.09.23
This product's status changed to Expired on 2024.09.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It also helps as an adjunctive treatment for partial seizures in epilepsy patients. It is effective in alleviating symptoms of fibromyalgia. Therefore, it is widely used for various neurological and pain-related disorders.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on the response and tolerability of each patient, the dose may be increased to 300 mg daily after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Although clinical studies have also been conducted at a dose of 600 mg daily, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplementary dose should be administered immediately after every 4 hours of hemodialysis. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplementary dose after hemodialysis: 25, 100, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: Supplementary dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age and adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behavior, so any mood changes or symptoms of depression should be reported to a healthcare professional immediately. It should not be taken if there is an allergy to any of its ingredients or if there are specific genetic diseases such as lactose intolerance. Diabetic patients should be cautious as weight gain may require adjustments to their blood sugar control medications. If serious allergic reactions such as angioedema occur, this medication should be discontinued immediately and a healthcare professional should be consulted. Elderly patients should be careful as dizziness or drowsiness may increase the risk of falls, and they should consult a healthcare professional if the symptoms are severe. If there are any changes in vision or blurred vision, they should be reported immediately. Abrupt discontinuation of this medication can lead to withdrawal symptoms like insomnia, headaches, and anxiety, so dosage should be reduced gradually as instructed by a healthcare professional. Due to the possibility of drug abuse or dependence, patients with a history of drug abuse should be particularly cautious and report any unusual behavior immediately. Patients with reduced kidney function may require dosage adjustment. Patients with heart disease should use this medication carefully due to the potential risk of heart failure. When used in conjunction with central nervous system depressants such as opioid analgesics, the risk of respiratory depression may increase, so caution is advised. Pregnant women are advised not to take this medication during early pregnancy due to the risk of fetal malformations and fertile women should use effective contraceptive methods. Breastfeeding women should discuss with their healthcare professional whether to discontinue nursing or this medication, as this drug can be passed into breast milk. During driving or operating machinery, care should be taken as dizziness and drowsiness can increase the risk of accidents. Serious skin reactions such as rashes, fevers, or mucosal damage may occur during the use of this medication, so any abnormal symptoms should lead to immediate discontinuation and reporting to a healthcare professional. In the case of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, requiring immediate medical attention.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 15℃ and 30℃. This will help preserve the medication's efficacy.
Hard capsule with a reddish-brown upper and white lower part containing white powder that is white or light yellow.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 75mg
Hard capsule · Prescription medication
Ahn-Gook New Pharm Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.